Davidr Spigel News Today

CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.Blinded independent review and study investigators separately determined a greater than 80% risk reduction for those treated with the osimertinib-based regimen, according to results presented at ASCO

A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer.

Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.

CHICAGO — Lorlatinib delivered never-before-seen PFS results in adults with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to findings from a randomized phase 3 trial presented at ASCO Annual Meeting.Lorlatinib (Lorbrena, Pfizer) also drastically delayed disease progression and development of brain metastases compared with crizotinib (Xalkori, Pfizer).

Phase 1 Trial of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced With Genetic and Epigenetic Reprogramming, in Advanced Triple-Negative...

Significant improvements in OS, PFS with durvalumab after CRT for unresectable disease